Aim 1:  Compare3 the molecular phenotypes of BLC and BRCA1-mutant breast cancers.

Aim 2:  Identify specific functional defects in DNA repair in BLC using DNA repair assays in viable tumor cells obtained from clinical samples.

Aim 3:  Access the response of a cohort of ER(-), PR(-), Her2(-) breast cancers to cis-platin in a phase II neo-adjuvant clinical trial and determine if results of informative assays developed above correlate with clinical response.

David M. Livingston, MD – DFCI

Daniel P. Silver, MD, PhD – DFCI

Judy E. Garber, MD, MPH – DFCI

Andrea Richardson, MD, PhD – BWH

Paula D. Ryan, MD, PhD – MGH

Zhigang (Charles) Wang, PhD – BWH

J. Dirk Iglehart, MD - DFCI

• 
• 
• 
  • Breast
    • Calendar
    • Cores
    • Developmental Research
    • Helpful Links
    • Investigators
    • Projects
    • Symposia/Events
  • Gastrointestinal Cancers
  • Lung
  • Myeloma
  • Ovarian
  • Prostate
  • Renal
  • Skin
• 
• 
• 
•